Молодежный инновационный вестникМолодежный инновационный вестник2415-7805Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации10431Conference ProceedingsPharmacotherapy of urinary tract infections in pregnant women: A comparative analysis of the preferences of obstetricians and gynecologists and doctors of therapeutic profileDanilovaMarina Sergeevna<p>Medical Institute, Medical Research and Educational Center, intern researcher, student</p>67cloud40@gmail.comhttps://orcid.org/0009-0000-1656-6517BontsevichRoman Aleksandrovich<p>Candidate of Medical Sciences, Associate Professor, Associate Professor of the Department of Internal Diseases No. 2 of the Mari State University; Associate Professor of the Department of Pharmacology and Clinical Pharmacology of the Belgorod State National Research University; Associate Professor of the Department of Clinical Pharmacology and Pharmacotherapy of the Kazan State Medical Academy &ndash; branch of the Federal State Budgetary Educational Institution of Higher Professional Education "Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation (KGMA&ndash;branch of the Federal State Budgetary Educational Institution of Higher Professional Education of the Russian Ministry of Health)</p>bontsevich_roman@mail.ruhttps://orcid.org/0000-0002-9328-3905Federal State Budgetary Educational Institution of Higher Education "Mari State University"Federal State Autonomous Educational Institution of Higher Education "Belgorod State National Research University" (NRU "BelSU")Kazan State Medical Academy - branch of the Federal State Budgetary Educational Institution of Additional Professional Education "Russian Medical Academy of Continuing Professional Education" Ministry of Health of the Russian Federation2504202514S14834842502202517032025Copyright © 2025, Danilova M.S., Bontsevich R.A.2025<p>Infectious diseases during pregnancy can lead to serious consequences for the fetus, including the threat of termination of pregnancy and premature birth. Improper administration of antibacterial therapy contributes to antibiotic resistance and causes side effects, while pregnant women are often excluded from clinical trials, which leads to a lack of data on the safety of medicines. The purpose of this study was to analyze the preferences of doctors of therapeutic profile and obstetricians and gynecologists (AiG) in the pharmacotherapy of urinary tract infections (UTIs) in pregnant women and assessment of their compliance with clinical recommendations. The study was conducted in 2018-2022 using the anonymous questionnaire method. 212 doctors from seven regions of Russia participated in the study. The results showed that 76.2% of participants indicated antimicrobial drugs (AMPS), while 89.2% of AiG and 63.8% of therapists prescribed AMPS (p0.001). The drug of choice was josamycin, indicated by 60.8% of AiG and 26.2% of therapists (p0.001).</p>antibacterial therapyinfectious diseasesantimicrobialsMycoplasmapharmacotherapyантибактериальная терапияинфекционные заболеванияантимикробные препаратыMycoplasmaфармакотерапия<p>Relevance. Any infectious diseases that occur during pregnancy can increase the risk of infection of the fetus, which in turn can lead to the threat of termination of pregnancy, premature birth and other complications. Improper administration of antibacterial therapy not only contributes to the growth of antibiotic resistance, but also causes various side effects, teratogenic effects and complications during pregnancy. The problem of choosing a suitable antimicrobial drug (AMP) and treatment errors in this group of women may be related to the fact that pregnant women are often excluded from clinical trials for ethical reasons, which leads to a lack of reliable data on the safety and efficacy of most medications.<br />The purpose of the study. To analyze and compare the preferences of doctors of therapeutic profile and obstetrician-gynecologists in the pharmacotherapy of urinary tract infections in pregnant women and assess their compliance with current clinical recommendations.<br />Materials and methods. "The study was conducted in 2018-2022 using the anonymous questionnaire method (pharmacoepidemiological knowledge cross-section) among doctors from seven regions/regions of Russia (Belgorod, Novosibirsk, Chelyabinsk, Moscow, Sakhalin, Voronezh regions and Krasnodar Territory). The author's full name of the study is The study of physicians' knowledge in antimicrobials use in pregnant women, abbreviated as PIKAP (the study was not registered in research registries on international clinical research portals and in the Russian Ministry of Health)" [1,2]. Qualitative variables were analyzed using four-field conjugacy tables and the chi-square criterion (2). If the values were less than 10, the chi-square criterion with the Yates correction was applied. A statistically significant difference was considered at the level of bilateral significance of p0.05. The subjects were asked to specify antimicrobial drugs (AMPS) prescribed when Mycoplasma (hominis or genitalium) bacteria were found in a pregnant woman. It was an open question. The rationale for choosing AMP was evaluated based on current clinical recommendations and treatment standards at the time of the study, and the safety of prescribed AMP for pregnant women was taken into account in accordance with European guidelines and recommendations [3-7]. <br />Results. 212 people participated in the study, including 142 doctors (66.8%) and 70 obstetricians and gynecologists (33.2%). In the first question, 163 people (76.2%) indicated AMP among all questionnaires, of which 89.2% of obstetricians and gynecologists prescribed AMP and only 63.8% of doctors of therapeutic profile (p0.001). Josamycin was the drug of choice for both obstetrician-gynecologists and doctors of the therapeutic profile: 60.8% of AIG doctors indicated it, 26.2% of doctors of the therapeutic profile (p0.001). At the same time, the second most popular AMP group among doctors of the therapeutic profile was macrolides 14.1%. An alternative drug was indicated by 28.4% of AIG doctors and 17.4% of therapeutic physicians (p=0.054). Both groups of subjects chose azithromycin as an alternative AMP 10.8% of AIG doctors and 6.7% of therapeutic physicians (p=0.415). <br />Conclusion. There is a lack of knowledge among doctors of the therapeutic profile regarding the treatment of bacteria of the genus Mycoplasma. Obstetricians and gynecologists more often chose a drug that meets clinical recommendations as the first line of therapy, as evidenced by the p-value.</p>1.Знания и предпочтения врачей в вопросах фармакотерапии беременных с инфекциями дыхательных путей: исследование PIKAP / Р. А. Бонцевич, А. А. Рябчикова, Т. И. Баламутова [и др.] // Медицинский совет. – 2024. – Т. 18, № 9. – С. 184-192. – DOI 10.21518/ms2024-052. – EDN NQCWAG.2.Предпочтения врачей в вопросах выбора лекарственных препаратов и тактики ведения беременных с бактериальными инфекциями мочеполовой системы. Исследование PIKAP / Р. А. Бонцевич, З.Ш.Валиева, О.Л.Пуганова [и др.] // Клиническая микробиология и антимикробная химиотерапия. – 2025. – Т. 27. – № 2. – в печати3.Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. Published 2021 Jul 23. doi:10.15585/mmwr.rr7004a14.Урогенитальные заболевания, вызванные Mycoplasma genitalium : Методические рекомендации № 21. – Москва : Типография "Нова Паблиш", 2022. – 24 с. – ISBN 978-5-6048718-3-6. – EDN FCLMHC.5.Клинические рекомендации. Инфекция мочевых путей при беременности - 2022. Доступно по адресу: https://cr.minzdrav.gov.ru/view-cr/719_1. Ссылка активна на 24 февраля 2025 г6.Bontsevich R.A., Adonina A.V., Gavrilova A.A., Vovk Y.R., Maximov M.L., Nevzorova V.A.. Rational antimicrobial chemotherapy: assessment of the level of basic knowledge of general practitioners. Final results of the KANT project. 2020. Research Results in Pharmacology. 2020;6(3):41-50. DOI: 10.3897/rrpharmacology.6.548557.Клинические рекомендации. Урогенитальные заболевания, вызванные Mycoplasma genitalium, 2024. Доступно по адресу: https://cr.minzdrav.gov.ru/view-cr/216_2. Ссылка активна на 24 февраля 2025 г.